Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility regarding their interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary Shares by six individuals on January 3, 2013. These acquisitions resulted from the reinvestment of dividends paid on shares held in the GlaxoSmithKline ShareReward Plan. The purchase price was 1,360.95 pence per Ordinary Share.
- Sir Andrew Witty: Acquisition of 24 Ordinary Shares
- Mr S Dingemans: Acquisition of 5 Ordinary Shares
- Mr S A Hussain: Acquisition of 8 Ordinary Shares
- Mr P C Thomson: Acquisition of 19 Ordinary Shares
- Dr P J T Vallance: Acquisition of 22 Ordinary Shares
- Mrs V A Whyte: Acquisition of 27 Ordinary Shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of director share interests.
Investor Verification Points
- Verify the share price of 1,360.95 pence per Ordinary Share on January 3, 2013.
- Confirm the total number of shares acquired by each listed director through the ShareReward Plan.
- Review the company's annual report (Form 20-F) for comprehensive financial performance data not included in this filing.